Buonomo O, Serao A, Muggianu A, Guglielmelli E, Davoli E, Amori A
Scuola di Specializzazione in Chirurgia d'Urgenza e di Pronto Soccorso, II Università degli Studi Tor Vergata, Roma.
G Chir. 1991 Apr;12(4):274-7.
Correlation between survival and hormonal receptor status in patients with breast cancer is still controversial. The results of a study carried out, from 1973 to 1988, on 55 patients (average age 56.7) affected with breast cancer and submitted to radical (Halsted) mastectomy, are reported. Estradiol receptors (ER) and progesterone receptors (PR) were determined using the dextran-coated charcoal (DCC) method and the enzymatic immuno assay (EIA). The threshold value for defining the ER positivity was 10 f/mole/mg of cytosol protein and 50 f/mole/mg for PR positivity. Forty-one patients resulted as ER+, 31 were also PR+. Moreover, 41 patients were treated with tamoxifen (10 mg x 2 die per os). In a 15-year follow-up, no significant difference in survival rate between patients with receptor-positive tumors or treated with tamoxifen and patients with receptor-negative tumors was recorded.
乳腺癌患者的生存率与激素受体状态之间的相关性仍存在争议。本文报告了一项于1973年至1988年对55例（平均年龄56.7岁）乳腺癌患者进行的研究结果，这些患者均接受了根治性（Halsted）乳房切除术。采用葡聚糖包被活性炭（DCC）法和酶免疫测定（EIA）法测定雌二醇受体（ER）和孕酮受体（PR）。定义ER阳性的阈值为10 f/摩尔/毫克细胞溶质蛋白，PR阳性为50 f/摩尔/毫克。41例患者为ER阳性，其中31例同时为PR阳性。此外，41例患者接受了他莫昔芬治疗（口服10毫克×每日2次）。在15年的随访中，受体阳性肿瘤患者或接受他莫昔芬治疗的患者与受体阴性肿瘤患者的生存率无显著差异。
